ArticleAnnals of surgical oncology2026
Surgical Management of Urachal Cancer in Germany: A Nationwide Analysis From 2006 to 2022.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- ASO Author Reflections: Surgical Management of Urachal Cancer in Germany: A Nationwide Analysis from 2006 to 2022.Annals of surgical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveUrachal cancer is a rare but highly aggressive malignancy. This study examined current trends in the surgical management of urachal cancer in Germany. MATERIAL &
methodsThe nationwide German hospital billing database (Destatis) and German quality reports were analyzed from 2006 to 2022. Identification of trends over time was performed using linear regression models.
resultsBetween 2006 and 2022, a total of 2593 cases were treated for urachal cancer in Germany. In 530 cases, a partial (n = 413) or radical (n = 117) cystectomy was performed. The share of partial cystectomy for treatment of urachal cancer increased from 52% in 2006 to 74% in 2022 (p<0.001). Radical cystectomy decreased from 48% in 2006 to 26% in 2022. Robotic-assisted partial cystectomy increased slightly from 9.7% in 2019 to 10.5% in 2022. The median age of patients undergoing partial cystectomy for urachal cancer increased from 57 ± 15.35 years in 2006 to 62 ± 12.59 years in 2022 (p<0.001). Median length of stay after open partial cystectomy decreased from 14 days in 2006 to 9 days in 2022 (p<0.001). Median length of stay for robotic-assisted partial cystectomy was 7 days in 2022. The mortality rate following partial cystectomy was 0.753%. The most common in-hospital complications associated with urachal cancer were hematuria in 1.19%, severe hemorrhage and hematoma in 0.96%, and paralytic ileus in 0.61%.
conclusionThis study demonstrates an increasing trend toward the use of partial cystectomy in the treatment of urachal cancer, along with a trend toward shorter hospital stays in recent years.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.